** Shares in Camurus CAMX.ST rise 10% after the Swedish biotech reported Q2 results above estimates

** Its revenue reached SEK 702 million ($72.8 million), above IBES estimates of SEK 632.8 million

** Jefferies says revenue beat was driven by sales of injectable opioid-use disorder drugs Brixadi and Buvidal, with $5 million milestone from partnership with Eli Lilly LLY.N already "in the numbers"

** Operating profit for the quarter was SEK 293 million, beating IBES estimate of SEK 232 million

** Higher revenues, with in-line gross margin and operating expenses drove up the operating profit beat, Jefferies says

** Jefferies estimates Camurus will resubmit an application to the FDA for its Oclaiz hormone disorder drug by Q4 this year

** Shares were up 10% at 07:01 GMT, on track for their best day since November 2025 if gains hold

($1 = 9.6490 Swedish crowns)